{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:31:51Z","timestamp":1791433911667,"version":"4.3.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023368","name":"Eisai Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12325-024-02811-2","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T11:01:24Z","timestamp":1709982084000},"page":"1728-1745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct04742699","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Motohiro","family":"Ozone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ariyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Hayashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsunari","family":"Habukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hiejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Kotorii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Murotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Taninaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohisa","family":"Uchimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,9]]},"reference":[{"key":"2811_CR1","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.sleep.2009.07.008","volume":"10","author":"MM Ohayon","year":"2009","unstructured":"Ohayon MM, Reynolds CF 3rd. Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD). Sleep Med. 2009;10:952\u201360.","journal-title":"Sleep Med"},{"key":"2811_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.sleep.2016.05.013","volume":"25","author":"O Itani","year":"2016","unstructured":"Itani O, Kaneita Y, Munezawa T, et al. Nationwide epidemiological study of insomnia in Japan. Sleep Med. 2016;25:130\u20138.","journal-title":"Sleep Med"},{"key":"2811_CR3","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.37765\/ajmc.2020.42769","volume":"26","author":"JA Dopheide","year":"2020","unstructured":"Dopheide JA. Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am J Manag Care. 2020;26:S76-84.","journal-title":"Am J Manag Care"},{"key":"2811_CR4","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1378\/chest.14-0970","volume":"146","author":"MJ Sateia","year":"2014","unstructured":"Sateia MJ. International Classification of Sleep Disorders\u2014third edition: highlights and modifications. Chest. 2014;146:1387\u201394.","journal-title":"Chest"},{"key":"2811_CR5","doi-asserted-by":"publisher","first-page":"ITC33","DOI":"10.7326\/AITC202103160","volume":"174","author":"EL Sutton","year":"2021","unstructured":"Sutton EL. Insomnia. Ann Intern Med. 2021;174:ITC33\u201348.","journal-title":"Ann Intern Med"},{"key":"2811_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.5664\/jcsm.27286","volume":"4","author":"S Schutte-Rodin","year":"2008","unstructured":"Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487\u2013504.","journal-title":"J Clin Sleep Med"},{"key":"2811_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/npr2.12205","volume":"41","author":"T Kishi","year":"2021","unstructured":"Kishi T, Nishida M, Koebis M, et al. Evidence-based insomnia treatment strategy using novel orexin antagonists: a review. Neuropsychopharmacol Rep. 2021;41:450\u20138.","journal-title":"Neuropsychopharmacol Rep"},{"key":"2811_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:307\u201349.","journal-title":"J Clin Sleep Med"},{"key":"2811_CR9","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1136\/bmj.38623.768588.47","volume":"331","author":"J Glass","year":"2005","unstructured":"Glass J, Lanct\u00f4t KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331:1169.","journal-title":"BMJ"},{"key":"2811_CR10","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.psychres.2015.11.003","volume":"230","author":"A Murakoshi","year":"2015","unstructured":"Murakoshi A, Takaesu Y, Komada Y, Ishikawa J, Inoue Y. Prevalence and associated factors of hypnotics dependence among Japanese outpatients with psychiatric disorders. Psychiatry Res. 2015;230:958\u201363.","journal-title":"Psychiatry Res"},{"key":"2811_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/npr2.12262","volume":"42","author":"SI Uemura","year":"2022","unstructured":"Uemura SI, Imanishi A, Terui Y, et al. Residual effects of low dose of suvorexant, zolpidem, and ramelteon in healthy elderly subjects: a randomized double-blind study. Neuropsychopharmacol Rep. 2022;42:288\u201398.","journal-title":"Neuropsychopharmacol Rep"},{"key":"2811_CR12","doi-asserted-by":"publisher","first-page":"1168100","DOI":"10.3389\/fpsyt.2023.1168100","volume":"14","author":"Y Takaesu","year":"2023","unstructured":"Takaesu Y, Sakurai H, Aoki Y, et al. Treatment strategy for insomnia disorder: Japanese expert consensus. Front Psychiatry. 2023;14:1168100.","journal-title":"Front Psychiatry"},{"key":"2811_CR13","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.3390\/jcm12072493","volume":"12","author":"NF Watson","year":"2023","unstructured":"Watson NF, Benca RM, Krystal AD, McCall WV, Neubauer DN. Alliance for Sleep Clinical Practice Guideline on switching or deprescribing hypnotic medications for insomnia. J Clin Med. 2023;12:2493.","journal-title":"J Clin Med"},{"key":"2811_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1017\/S0714980816000702","volume":"36","author":"C Tannenbaum","year":"2017","unstructured":"Tannenbaum C, Farrell B, Shaw J, et al. An ecological approach to reducing potentially inappropriate medication use: Canadian Deprescribing Network. Can J Aging. 2017;36:97\u2013107.","journal-title":"Can J Aging"},{"key":"2811_CR15","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/jgs.13702","volume":"63","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2015","unstructured":"American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227\u201346.","journal-title":"J Am Geriatr Soc"},{"key":"2811_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/jsr.12594","volume":"26","author":"D Riemann","year":"2017","unstructured":"Riemann D, Baglioni C, Bassetti C, et al. K. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26:675\u2013700.","journal-title":"J Sleep Res"},{"key":"2811_CR17","unstructured":"ClinicalTrials.gov. Facilitation of zolpidem (\u226510 mg) discontinuation through use of ramelteon in subjects with chronic insomnia. Last updated 2010-07-20. Available at https:\/\/clinicaltrials.gov\/study\/NCT00492232. Accessed 06 July 2023."},{"key":"2811_CR18","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","volume":"16","author":"C Muehlan","year":"2020","unstructured":"Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opin Drug Metab Toxicol. 2020;16:1063\u201378.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2811_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa123","volume":"43","author":"M K\u00e4rpp\u00e4","year":"2020","unstructured":"K\u00e4rpp\u00e4 M, Yardley J, Pinner K, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020;43:zsaa123.","journal-title":"Sleep"},{"key":"2811_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18254","volume":"2","author":"R Rosenberg","year":"2019","unstructured":"Rosenberg R, Murphy P, Zammit G, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open. 2019;2:e1918254.","journal-title":"JAMA Netw Open"},{"key":"2811_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleepx.2023.100098","volume":"7","author":"M Ahmad","year":"2024","unstructured":"Ahmad M, Kelly J, Montano B, et al. Transitioning insomnia patients from zolpidem to lemborexant: a multicenter, open-label study evaluating a next-dose transition approach to insomnia pharmacotherapy. Sleep Med X. 2024;7:10098. https:\/\/doi.org\/10.1016\/j.sleepx.2023.100098.","journal-title":"Sleep Med X"},{"key":"2811_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/pcn5.32","volume":"1","author":"K Usui","year":"2022","unstructured":"Usui K, Fujii Y, Okada K, Suzuki E. Low-dose benzodiazepine receptor agonists may be completely replaced by lemborexant at about the same dose. Psychiatry Clin Neurosci Reports. 2022;1:e32.","journal-title":"Psychiatry Clin Neurosci Reports"},{"key":"2811_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/pcn5.23","volume":"1","author":"T Kishi","year":"2022","unstructured":"Kishi T, Sakuma K, Okuya M, Iwata N. Lemborexant for insomnia in adults with psychiatric disorders: a 1-week, open-label study. Psychiatry Clin Neurosci Reports. 2022;1:e23.","journal-title":"Psychiatry Clin Neurosci Reports"},{"key":"2811_CR24","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association; 2013.","edition":"5"},{"key":"2811_CR25","unstructured":"Eisai Co., Ltd. Japanese package insert of DAYVIGO (lemborexant). 2022. Available at https:\/\/www.info.pmda.go.jp\/go\/pdf\/170033_1190027F1022_1_04"},{"key":"2811_CR26","unstructured":"Eisai Inc. US prescribing information of DAYVIGO (lemborexant). 2023. Available at https:\/\/www.dayvigo.com\/-\/media\/Files\/DAYVIGO\/PDF\/prescribing-information.pdf"},{"key":"2811_CR27","unstructured":"MSD K.K. Japanese package insert of Belsomra (suvorexant). 2023. Available at https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00066563.pdf"},{"key":"2811_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2868","volume":"38","author":"K Okino","year":"2023","unstructured":"Okino K, Suzuki H, Tomioka H, et al. Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma-aminobutyric acid-benzodiazepine receptor agonists or suvorexant. Hum Psychopharmacol. 2023;38:e2868.","journal-title":"Hum Psychopharmacol"},{"key":"2811_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0140-6736(22)00878-9","volume":"400","author":"F De Crescenzo","year":"2022","unstructured":"De Crescenzo F, D\u2019Al\u00f2 GL, Ostinelli EG, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400:170\u201384.","journal-title":"Lancet"},{"key":"2811_CR30","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1177\/0091270006293303","volume":"46","author":"DJ Greenblatt","year":"2006","unstructured":"Greenblatt DJ, Legangneux E, Harmatz JS, et al. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol. 2006;46:1469\u201380.","journal-title":"J Clin Pharmacol"},{"key":"2811_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1472-8206.2006.00415.x","volume":"20","author":"E Weinling","year":"2006","unstructured":"Weinling E, McDougall S, Andre F, Bianchetti G, Dubruc C. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundam Clin Pharmacol. 2006;20:397\u2013403.","journal-title":"Fundam Clin Pharmacol"},{"key":"2811_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jpsychires.2020.05.025","volume":"128","author":"T Kishi","year":"2020","unstructured":"Kishi T, Nomura I, Matsuda Y, et al. Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis. J Psychiatr Res. 2020;128:68\u201374.","journal-title":"J Psychiatr Res"},{"key":"2811_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/npr2.12069","volume":"39","author":"T Kishi","year":"2019","unstructured":"Kishi T, Sakuma K, Okuya M, et al. Suvorexant for insomnia in patients with psychiatric disorder: a 1-week, open-label study. Neuropsychopharmacol Rep. 2019;39:252\u20135.","journal-title":"Neuropsychopharmacol Rep"},{"key":"2811_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.9758\/cpn.2018.16.2.184","volume":"16","author":"M Hatano","year":"2018","unstructured":"Hatano M, Kamei H, Inagaki R, et al. Assessment of switching to suvorexant versus the use of add-on suvorexant in combination with benzodiazepine receptor agonists in insomnia patients: a retrospective study. Clin Psychopharmacol Neurosci. 2018;16:184\u20139.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"2811_CR35","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/psyg.12858","volume":"22","author":"K Okino","year":"2022","unstructured":"Okino K, Suzuki H, Kondo S, et al. Effectiveness of change from suvorexant to lemborexant drug in the treatment of sleep disorders. Psychogeriatrics. 2022;22:595\u2013604.","journal-title":"Psychogeriatrics"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02811-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02811-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02811-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T09:36:52Z","timestamp":1711186612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02811-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,9]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2811"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02811-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,9]]},"assertion":[{"value":"21 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Motohiro Ozone received grants from Mitsubishi Tanabe Pharma Corporation, Tsumura Co., Ltd., Shionogi & Co., Ltd., Mochida Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., and Teijin Pharma Ltd.; and honoraria from Eisai Co., Ltd., Tsumura Co., Ltd., MSD Co., Ltd., Meiji Seika Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Nobelpharma Co., Ltd., Yoshitomi Pharmaceutical Industries, Ltd., and Mitsubishi Tanabe Pharma Corporation. Susumu Hirota received consulting fees from Viatris Inc.; honoraria from Eisai Co., Ltd., Meiji Seika Pharma Co., Ltd., Sumitomo Pharma Co., Ltd., and Takeda Pharmaceutical Company Ltd.; and is involved in clinical trials with Nippon Boehringer Ingelheim Co., Ltd., Shiongi & Co., Ltd., Sumitomo Pharma Co., Ltd., and Viatris Inc. Yu Ariyoshi received honoraria from Eisai Co., Ltd. and MSD Co., Ltd. Kenichi Hayashida received lecture fees from Eisai Co., Ltd. and MSD Co., Ltd. Azusa Ikegami received honoraria from Eisai Co., Ltd. Mitsunari Habukawa received honoraria from Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., MSD Co., Ltd., and Takeda Pharma Co., Ltd., Nozomu Kotorii received consulting fees from Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, MSD Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., and Janssen Pharmaceutical K.K. Takehiro Taninaga is an employee of Eisai Co., Ltd. Naohisa Uchimura received honoraria from Eisai Co., Ltd., Meiji Seika Pharma Co., Ltd., MSD Co., Ltd., Nobelpharma Co., Ltd., and Takeda Pharmaceutical Company Limited. The remaining authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by the NPO Clinical Research Network Fukuoka Certified Review Board and was registered at ClinicalTrials.gov under the identifier NCT04742699. The study adhered to the Declaration of Helsinki of 1964 and its later amendments, the Clinical Trials Act (Japanese law), and local regulations. All patients provided informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}